☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended: October 1, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (State or other jurisdiction of incorporation or organizatio ...

Haemonetics Corporation (NYSE:HAE) Q2 2023 Earnings Conference Call November 7, 2022 8:00 AM ET Company Participants Olga Guyette - Director, Investor Relations and Treasury Chris Simon - Chief Executive Officer Stewart Strong - President of Global Hospital Business James D'Arecca - Chief Financial Officer Conference Call Participants Anthony Petrone - Mizuho Drew Ranieri - Morgan Stanley Andrew Cooper - Raymond James David Turkaly - JMP Securities Mike Matson - Needham & Company Operator Good day, and welc ...

Haemonetics Corporation Morgan Stanley 20th Annual Global Healthcare Conference September 12, 2022 © 2022 Haemonetics Corporation IMPORTANT INFORMATION 2 Safe Harbor for Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as "may," "wi ...

Haemonetics Corporation (NYSE:HAE) Q1 2023 Earnings Conference Call August 10, 2022 8:00 AM ET Company Participants Olga Guyette - Director, IR and Treasury Chris Simon - CEO James D’Arecca - CFO Conference Call Participants Larry Solow - CJS Securities Drew Ranieri - Morgan Stanley Andrew Cooper - Raymond James Mike Matson - Needham & Company Michael Petusky - Barrington Research David Turkaly - JMP Securities Anthony Petrone - Mizuho Securities Operator Good day, and welcome to Haemonetics Corporation's F ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q For the quarterly period ended: July 2, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorporation or organization) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 2, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 (State or other jurisdiction of incorpora ...

Haemonetics Corporation (NYSE:HAE) Q4 2022 Results Conference Call May 10, 2022 8:00 AM ET Company Participants Olga Guyette - Director, IR and Treasury Chris Simon - CEO James D’Arecca - CFO Conference Call Participants Larry Solow - CJS Securities Drew Ranieri - Morgan Stanley Andrew Cooper - Raymond James Mike Matson - Needham & Company David Turkaly - JMP Securities Operator Good morning, ladies and gentlemen. Thank you for standing by, and welcome to Haemonetics Corporation Fourth Quarter Fiscal 2022 E ...

Haemonetics Corporation Raymond James 43rd Institutional Investors Conference March 7-8, 2022 © 2022 Haemonetics Corporation Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may constitute forward-looking statements. Forward-looking statements in this presentation may include, without limitation, statements regarding (i) plans and objectives of management for operations of Haemonetics Corporation (the "Company"), including plans or objectives rel ...

Haemonetics Corporation (NYSE:HAE) Q3 2022 Results Conference Call February 8, 2022 8:00 AM ET Company Participants Olga Guyette - Director, IR Christopher Simon - President, CEO William Burke - CFO Conference Call Participants Zach Weiner - Jefferies Andrew Cooper - Raymond James Mike Matson - Needham & Company Drew Ranieri - Morgan Stanley Larry Solow - CJS Securities Operator Good day, and thank you for standing by. Welcome to the Haemonetics Corporation's Third Quarter Fiscal 2022 Earnings Call. [Operat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 For the quarterly period ended: January 1, 2022 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF ☐ 1934 Commission File Number: 001-14041 HAEMONETICS CORPORATION (Exact name of registrant as specified in its charter) Massachusetts 04-2882273 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 (781) 848-7100 (Registrant's telephone number, including are ...